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Authors’ Response to Comments Regarding Risperidone 
versus Olanzapine Markov Model
It is our normal editorial policy to allow authors of
articles published in Value in Health to reply to
letters about their article in the same journal issue.
In this case, we inadvertently did not notify the
authors of the letter about their article and so their
response is being published in a later issue. We apol-
ogize to the authors for our error in this case.
Josephine Mauskopf, PhD
Editor-in-Chief
Value in Health
To the Editor—We appreciate the interest of Drs.
Clewell and Baker in our research article “Out-
comes and costs of risperidone vs. olanzapine in
patients with chronic schizophrenia or schizoaffec-
tive disorders: a Markov model” (Value in Health
2004,7:569–84) and would like to address some of
the issues raised in their Letter to the Editor pub-
lished in Value in Health 2005,8:175–6.
Their statement that “models are of greatest
value when they lead us to new, unintuitive predic-
tions about the relationships between variables”
captures the essence of our research objectives. Our
model focused particular attention on the likelihood
of therapy switching and discontinuation as a result
of treatment-emergent side effects. To the best of
our knowledge, our model is the ﬁrst to examine the
clinical and economic implications of differences in
the tolerability of atypical antipsychotic agents—in
particular, therapy-related weight gain. Increasing
awareness of the link between adiposity and adverse
health and economic outcomes has led to recom-
mendations for closer monitoring and more aggres-
sive management in this patient population.
Drs Clewell and Baker found the discontinuation
rates resulting from our model inconsistent with
certain data which they cite in their letter. In our
article, we recognized that our model could produce
estimates of discontinuation over 1 year that are
inconsistent with research from shorter time periods
or studies that did not account for side effects. We
believe this highlights the contribution of our model
to the current body of literature, beyond what is
available even from naturalistic studies.
We do not believe that our assumptions regard-
ing therapy discontinuation in relation to change in
body weight are “arbitrarily set at a high level.”
Our assumptions are supported by the statement
from the Consensus Development Conference on
Antipsychotic Drugs and Obesity and Diabetes con-
vened by the American Diabetes Association, the
American Psychiatric Association, the American
Association of Clinical Endocrinologists, and the
North American Association for the Study of Obes-
ity, which reads: “If a patient gains ≥5% of his or
her initial weight at any time during therapy, one
should consider switching the SGA (second-
generation antipsychotic)” [1]. The recommenda-
tion of the consensus panel also is consistent with
the FDA’s deﬁnition of “signiﬁcant” weight gain,
and other expert recommendations that were orig-
inally referenced in our publication. Moreover, we
undertook extensive sensitivity analyses in which
we examined the impact on model ﬁndings of var-
ying the probability of therapy discontinuation fol-
lowing increases in body weight. As we reported,
this probability would have to be less than 0.1 for
the proportion of patients remaining on therapy at
the end of 1 year to be the same for risperidone and
olanzapine.
Drs Clewell and Baker claim that available evi-
dence is insufﬁcient to draw the conclusion that
“risperidone treatment is less likely to be associated
with treatment-emergent diabetes than olanzapine
treatment.” Although we did not draw any conclu-
sions on this issue, the model did incorporate esti-
mates of the monthly risk of diabetes for each
product. These were calculated by pooling data
across eight studies (using a random-effects model).
The estimated annual incidence of diabetes was
1.5% for risperidone and 2.3% for olanzapine. We
feel these estimates are in line with the existing body
of evidence and we stand by the methods used to
generate them.
As researchers, we acknowledge the limitations
of models generally, and more speciﬁcally the limi-
tations of this particular model; in fact, we discuss
these extensively in our article. One of the beneﬁts
of such models, however, is their ability to test the
impact of alternative assumptions or parameter esti-
mates on research ﬁndings and implications. Our
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sensitivity analysis, also detailed in the article,
showed that our results were quite robust with
respect to changes in our assumptions and esti-
mates. We remain conﬁdent in the rigor and
appropriateness of our research.—Montserrat Vera-
Llonch, MD, MPH, Thomas E. Delea, MSIA, Erin
Richardson, BS, Gerry Oster, PhD, Policy Analysis
Inc. (PAI), Brookline, MA; Marcia Rupnow, PhD,
Janssen Medical Affairs, LLC, Titusville, NJ; and
Amy Grogg, PharmD, Applied Health Outcomes,
Palm Florida, FL.
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